Aicar: A Literature Course on What Published Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision related to the compounds discussed here. Nothing below is a protocol, a recommendation, or a statement that any outcome will occur in humans.

Module 1: What AICAR Is and How It Has Been Studied

AICAR stands for 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside. In the literature it also appears as AICAr, acadesine, and AICA riboside. Chemically it is a nucleoside analogue: a ribose sugar joined to an imidazole carboxamide base. It contains no amino acids and no peptide bonds, so despite the phrase "aicar peptide" circulating online, AICAR is not a peptide and is not structurally related to peptide compounds such as growth-hormone secretagogues.

Its biochemical origin is the de novo purine synthesis pathway. The phosphorylated form of AICAR — AICAR monophosphate, conventionally abbreviated ZMP — is a natural intermediate in that pathway. Because ZMP resembles AMP, cells that take up and phosphorylate exogenous AICAR accumulate an AMP-like signal, which is the basis for its use as a laboratory AMPK activator.

Forms used in published work

• Cell-culture solution. Researchers added AICAR directly to medium in C2C12 myotubes, where the study examined mitochondrial biogenesis and branched-chain amino acid catabolic enzyme expression (PMID 34798200), and in myelodysplastic syndrome cell models, where the study reported suppressed cell proliferation and synergy with decitabine (PMID 33788127).
• Injected aqueous solution in rodents. Systemic administration was used in models of intestinal ischemia and reperfusion (PMID 25611433), acute lung injury (PMID 34049949), corneal allograft transplantation in mice (PMID 30856534) and high-fat-diet-induced metabolic syndrome in C57Bl/6 male mice (PMID 36555360).
• Engineered delivery systems. A 2025 report described a liposome-encapsulated AICAR hydrogel evaluated in osteoarthritis, where the study attributed effects to macrophage metabolic reprogramming via SIK1 activation (PMID 40616103).
• Analytical reference material. Anti-doping chemists worked with AICAr and its metabolites to build detection methods, and one study proposed the AICAr-to-SAICAr ratio as an additional marker of AICAr use (PMID 36342242).

Limits of the evidence in Module 1

The verified literature summarised here contains no controlled human efficacy trial. Nomenclature is inconsistent across papers, formulations differ substantially (free compound in medium versus a liposomal hydrogel), and characterisation of the material used — purity, vehicle, stability — is described only inside individual papers, not in any shared standard. Nothing in this module establishes that laboratory findings transfer to people.

Module 2: Mechanism as Described in the Literature

The AMPK pathway

The recurring mechanistic claim across these papers is activation of AMP-activated protein kinase. A 2024 report on diabetic polyneuropathy described AICAR explicitly as an AMPK activator and attributed its effects to regulation of mitophagy (PMID 39795939). In a kidney ischemia-reperfusion model, researchers reported modulation of the AMPK–TXNIP–NLRP3 pathway together with changes in energy metabolism (PMID 41644729). In acute lung injury, the study reported that AICAR phosphorylated AMPK and upregulated heme oxygenase-1 (PMID 34049949).

Downstream branches reported

• Mitochondrial and metabolic gene programmes. In C2C12 myotubes the study reported stimulation of mitochondrial biogenesis alongside increased expression of BCAA catabolic enzymes (PMID 34798200).
• mTOR suppression. In the mouse corneal allograft model, researchers described prolonged graft survival via the AMPK–mTOR signalling axis (PMID 30856534).
• Antioxidant transcription. A 2025 cardiomyocyte study reported that AICAr inhibited autophagy and promoted p62-dependent NRF2 expression, which the authors linked to protection against doxorubicin toxicity (PMID 41231272).
• Immune-cell metabolism. The osteoarthritis hydrogel study framed benefit in its model as macrophage metabolic reprogramming downstream of SIK1 activation (PMID 40616103).
• Inflammatory signalling. The intestinal ischemia-reperfusion study reported attenuation of organ injury and of the systemic inflammatory response (PMID 25611433).

Mechanisms that are not AMPK, and conditions that block AMPK

Two papers complicate the simple "AICAR equals AMPK activation" story. In myelodysplastic syndrome models, the study attributed suppressed proliferation and synergy with decitabine to DNA damage induction rather than to a purely metabolic effect (PMID 33788127). Separately, a cell-physiology study reported that nucleosides blocked AICAR-stimulated activation of AMPK in skeletal muscle and cancer cells, meaning the extracellular nucleoside environment altered whether the compound signalled at all (PMID 30230919).

Limits of the evidence in Module 2

Mechanistic pathways were inferred largely from pathway inhibitors, knockdowns and phosphorylation readouts in specific cell types. Because ZMP mimics AMP rather than acting as a selective drug at a single receptor, off-target effects on other AMP-sensitive enzymes cannot be excluded from these designs, and the nucleoside-blocking result (PMID 30230919) shows that mechanism is context-dependent.

Module 3: Reported Outcomes by Study

The table below summarises the models, endpoints and reported results of the verified papers. It is a description of what researchers observed in their own systems, not a list of benefits. No doses are stated here because dose regimens are specified inside the individual publications and are not reproduced on this page.

Limits of the evidence in Module 3

Every row is a single-laboratory result in an animal or cell system, most with short observation windows and surrogate endpoints such as injury scores, enzyme expression or graft survival in mice. Several models are acute-injury paradigms in which a protective signal may not predict anything about healthy physiology. No head-to-head human comparison, no long-term follow-up and no independent replication across laboratories is represented in this set, and none of these reports describes performance, body-composition or longevity outcomes in people.

Module 4: Aicar Side Effects: What Studies Report

The verified literature does not contain a dedicated human safety or toxicology study, so what follows is limited to adverse, cytotoxic or otherwise unfavourable findings that appear inside the published reports themselves.

• Antiproliferative and genotoxic activity. The most directly relevant safety-adjacent finding is that researchers reported DNA damage induction as the mechanism by which AICAR suppressed proliferation in myelodysplastic syndrome cells (PMID 33788127). DNA damage was the desired effect in a cancer-directed experiment, but it is a biological action that would not be selective for diseased cells by definition in that report.
• Autophagy inhibition in heart cells. A 2025 cardiomyocyte study reported that AICAr inhibited autophagy, with protection against doxorubicin attributed to the resulting p62-dependent NRF2 signal (PMID 41231272). Autophagy inhibition is a two-edged intervention in cardiac biology, and this report describes it in a specific chemotherapy-toxicity context only.
• Immunosuppressive direction of effect. The corneal transplantation study reported prolonged allograft survival via AMPK–mTOR signalling (PMID 30856534), which describes dampened alloimmune activity — an effect class that in principle carries immunological trade-offs, though the study did not characterise them.
• Signal unreliability rather than toxicity. A cell-physiology study reported that nucleosides blocked AICAR-stimulated AMPK activation in skeletal muscle and cancer cells (PMID 30230919), which is a reproducibility and interaction concern rather than an adverse event.
• Detectability as a practical consequence. Anti-doping researchers reported a urinary AICAr-to-SAICAr ratio approach as an additional marker of AICAr use (PMID 36342242).

Limits of the evidence in Module 4

Absence of reported adverse events in preclinical efficacy papers is not evidence of safety: those studies were not designed or powered to detect harm, rarely followed animals long term, and did not report standardised adverse-event tables. No organ-system safety profile, no drug-interaction study in humans, and no data in pregnancy, paediatric or renally impaired populations appear in this verified set.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic data in the verified set are sparse. The clearest disposition-related information comes from analytical chemistry: the study that proposed the AICAr-to-SAICAr ratio worked with urinary AICAr and its metabolite SAICAr, indicating that AICAr and related purine-pathway metabolites are measurable in urine and that endogenous background concentrations complicate interpretation (PMID 36342242). That endogenous background is a defining pharmacokinetic problem for this compound: because AICAR-related species occur naturally, distinguishing administered from endogenous material required a ratio-based approach in that study.

Cellular uptake is also relevant to exposure. Researchers reported that nucleosides blocked AICAR-stimulated AMPK activation in muscle and cancer cells (PMID 30230919), a result consistent with competition at nucleoside transport and with the requirement that AICAR be taken up and phosphorylated intracellularly before it can act. Route differences across the models are visible too: systemic injection was used in rodent injury models such as intestinal ischemia-reperfusion (PMID 25611433), while a localised depot approach was tested as a liposome-encapsulated hydrogel in osteoarthritis (PMID 40616103).

Limits of the evidence in Module 5

No human absorption, bioavailability, half-life, clearance, volume-of-distribution or dose-proportionality values appear in the verified set. Oral bioavailability is not characterised here at all. Tissue distribution in the models above was inferred from downstream pharmacodynamic readouts rather than measured concentrations, and interspecies scaling from rodents is not supported by these data.

Module 6: Regulatory Status, Stated Factually

Approved products

AICAR, also known as acadesine, has been studied in clinical development programmes historically, but the verified literature summarised on this page contains no approved-product label and no registrational trial. On that basis, this page does not describe AICAR as an approved medicine for any indication in any jurisdiction.

Research-use-only material

Material supplied for laboratory work is typically labelled research use only (RUO), meaning it is intended for in vitro and animal investigation and is not represented as suitable for diagnostic or therapeutic use in humans. The cell and rodent studies cited throughout this page — for example the C2C12 myotube work on mitochondrial biogenesis and BCAA enzyme expression (PMID 34798200) and the high-fat-diet mouse study on metabolic syndrome outcomes (PMID 36555360) — represent that category of use.

Compounding

In the United States, pharmacy compounding of a bulk drug substance under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that the substance be a component of an FDA-approved drug, be the subject of an applicable USP or NF monograph, or appear on an FDA bulk drug substances list. A substance without approved-product status does not meet the first of those conditions.

Sport regulation

AICAR is treated as an anti-doping analytical target, which is why a drug-testing study developed the AICAr-to-SAICAr ratio as an additional marker of use (PMID 36342242). Athletes in tested sport are subject to their governing body's current prohibited list, which changes annually.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and changes over time; the statements above describe general frameworks, not the status of any particular product. This is general information and not legal advice, and it is not medical advice either.

What the Studies Did Not Test

Reading across the verified set, the gaps are larger than the findings:

1. Healthy human physiology. Every efficacy result above came from a cell line or an animal disease model, including diabetic polyneuropathy (PMID 39795939) and renal ischemia-reperfusion (PMID 41644729); none tested healthy people.
2. Exercise performance or body composition in humans. Although mitochondrial biogenesis was reported in cultured myotubes (PMID 34798200), no human endurance, strength or fat-mass endpoint appears in this literature set.
3. Long-term safety. No chronic-toxicity, carcinogenicity or reproductive-toxicity study is represented, and the one paper describing DNA damage did so in a cancer-cell context (PMID 33788127).
4. Comparative effectiveness. No study here compared AICAR with exercise, metformin or any standard therapy in a human population.
5. Dose-response in humans and route equivalence. Rodent injection protocols such as those used in acute lung injury work (PMID 34049949) and localised hydrogel delivery in joints (PMID 40616103) are not interchangeable, and no bridging human data exist in this set.
6. Interactions. Only one paper addressed a modifier of activity, reporting that nucleosides blocked AICAR-stimulated AMPK activation (PMID 30230919).

Readers interested in this compound are best served by reading the primary papers directly and by discussing any health question with a licensed clinician. This course describes published research; it does not recommend, endorse or instruct any use.

References

• Liposome-encapsulated AICAR hydrogel regulates macrophage metabolic reprogramming via SIK1 activation to alleviate osteoarthritis (Journal of Nanobiotechnology, 2025)
• Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy (International Journal of Molecular Sciences, 2024)
• AICAR attenuates ischemia-reperfusion-induced AKI by modulating AMPK-TXNIP-NLRP3 pathway and energy metabolism (Cellular and Molecular Life Sciences, 2026)
• AICAR stimulates mitochondrial biogenesis and BCAA catabolic enzyme expression in C2C12 myotubes (Biochimie, 2022)
• AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction (Biotechnology Letters, 2021)
• AICAr to SAICAr ratio can serve as additional marker of AICAr use (Drug Testing and Analysis, 2022)
• AICAR decreases acute lung injury by phosphorylating AMPK and upregulating heme oxygenase-1 (European Respiratory Journal, 2021)
• AICAr inhibition of cardiomyocyte autophagy promotes p62-dependent NRF2 expression and protection against doxorubicin toxicity (Cellular and Molecular Life Sciences, 2025)
• AICAR prolongs corneal allograft survival via the AMPK-mTOR signaling pathway in mice (Biomedicine & Pharmacotherapy, 2019)
• Nucleosides block AICAR-stimulated activation of AMPK in skeletal muscle and cancer cells (American Journal of Physiology: Cell Physiology, 2018)
• AICAR attenuates organ injury and inflammatory response after intestinal ischemia and reperfusion (Molecular Medicine, 2015)
• AICAR Improves Outcomes of Metabolic Syndrome and Type 2 Diabetes Induced by High-Fat Diet in C57Bl/6 Male Mice (International Journal of Molecular Sciences, 2022)